These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38296617)

  • 1. Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
    Nachmias B; Aumann S; Haran A; Schimmer AD
    Br J Haematol; 2024 Apr; 204(4):1146-1158. PubMed ID: 38296617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.
    Shahswar R; Ganser A
    Expert Rev Hematol; 2024 Oct; 17(10):723-739. PubMed ID: 39246164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia.
    Aumann S; Shaulov A; Haran A; Gross Even-Zohar N; Vainstein V; Nachmias B
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax-based therapies for acute myeloid leukemia.
    Guerra VA; DiNardo C; Konopleva M
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
    Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
    Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
    Huemer F; Melchardt T; Jansko B; Wahida A; Jilg S; Jost PJ; Klieser E; Steiger K; Magnes T; Pleyer L; Greil-Ressler S; Rass C; Greil R; Egle A
    Eur J Haematol; 2019 May; 102(5):437-441. PubMed ID: 30725494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia.
    Lu Y; Jiang X; Li Y; Li F; Zhao M; Lin Y; Jin L; Zhuang H; Li S; Ye P; Pei R; Jin J; Jiang L
    J Transl Med; 2024 Sep; 22(1):867. PubMed ID: 39334157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
    Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM
    Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
    Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia.
    Makowka P; Stolp V; Stoschek K; Serve H
    Biol Chem; 2021 Nov; 402(12):1547-1564. PubMed ID: 34700366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.
    Karol SE; Alexander TB; Budhraja A; Pounds SB; Canavera K; Wang L; Wolf J; Klco JM; Mead PE; Das Gupta S; Kim SY; Salem AH; Palenski T; Lacayo NJ; Pui CH; Opferman JT; Rubnitz JE
    Lancet Oncol; 2020 Apr; 21(4):551-560. PubMed ID: 32171069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects for Venetoclax in Myelodysplastic Syndromes.
    Garcia JS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):441-448. PubMed ID: 32089221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis targeted therapies in acute myeloid leukemia: an update.
    Ball S; Borthakur G
    Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
    [No Abstract]   [Full Text] [Related]  

  • 19. SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies.
    Forsberg M; Konopleva M
    Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):1-14. PubMed ID: 38007372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
    Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
    Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.